The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy, the deadly neurological disorder amyotrophic lateral sclerosis, and more.
Xconomy previewed the conference last week. Today we’re circling back to sort through the news and put it in context.
SPINAL MUSCULAR ATROPHY
The treatment landscape for spinal muscular atrophy, or SMA, a rare and potentially lethal genetic disease, is about to change. Until the 2016 approval of nusinersen (Spinraza) from… Read more »
UNDERWRITERS AND PARTNERS